par Creteur, Jacques ;Vincent, Jean Louis
Référence Critical care clinics, 25, 2, page (311-324)
Publication Publié, 2009-04
Article révisé par les pairs
Résumé : Hemoglobin-based oxygen carriers (HBOCs) were initially developed to provide an alternative to blood transfusion. With the realization that hemoglobin solutions not only are red blood cell substitutes but also have a number of additional properties, including hemodynamic effects related to their oncotic and nitric oxide-scavenging effects, the broader concept of "hemoglobin therapeutics" was born. Promising effects on oxygen transport and the microcirculation need to be confirmed, and the results of studies with newer, second-generation HBOCs are eagerly awaited. In the meantime, possible adverse effects need to be carefully evaluated before HBOCs can be widely used in the ICU, emergency room, or prehospital setting. © 2009 Elsevier Inc. All rights reserved.